Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes

Iris M. de Lange*, Boudewijn Gunning, Anja C. M. Sonsma, Lisette van Gemert, Marjan van Kempen, Nienke E. Verbeek, Joost Nicolai, Nine V. A. M. Knoers, Bobby P. C. Koeleman, Eva H. Brilstra

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1154-1165
Number of pages12
JournalEpilepsia
Volume59
Issue number6
DOIs
Publication statusPublished - Jun 2018

Keywords

  • cognition
  • Dravet syndrome
  • GEFS
  • SCN1A
  • sodium-channel blockers
  • SEVERE MYOCLONIC EPILEPSY
  • LONG-TERM COURSE
  • SCN1A MUTATIONS
  • FEBRILE SEIZURES
  • SODIUM-CHANNEL
  • INFANCY
  • DIAGNOSIS
  • VARIANTS
  • GENE
  • ENCEPHALOPATHY

Cite this